Li Li
5 Papers
Li Li is an academic researcher. The author has contributed to research in topics: Cyclin-dependent kinase 1 & Cancer. The author has co-authored 1 publications.
Chat about Author
Papers
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b Results.
Ezra Y. Rosen,T.A. Yap,Elisa Fontana,Elizabeth K. Lee,D. Mahalingam,Martin Højgaard,Niharika B. Mettu,Gregory M. Coté,Ruth Plummer,Maria Koehler,Danielle Ulanet,Kezhen Fei,Ian M. Silverman,J. Schonhoft,V. Rimkunas,E. Bacque,Gabriela Gomez,Adrian J. Fretland,Anne Roulston,Li Li,Prasamit S Baruah,Michal Zimmermann,Julia Yang,Benedito A. Carneiro,Stephanie Lheureux +24 more
TL;DR: Camonsertib, an ATRi, in combination with low-dose gemcitabine, showed preliminary clinical activity in solid tumors with DNA damage response aberrations, with tumor responses observed in gynecological cancers, but further evaluation is warranted due to challenging tolerability.
Abstract 5650: RP-6306, a novel PKMYT1 inhibitor, demonstrates synthetic lethality as monotherapy and in combination with gemcitabine in CCNE1 amplified cancer cells
Jimmy Fourtounis,John Martino,Rino Stocco,Prasamit S Baruah,Nicole M. Duffy,David Gallo,S. Fournier,Jingjing Li,Li Li,E. G. Aguado,Adam Petrone,Anne Roulston,Yael Mamane,S. Morris,Janek Szychowski,Robert Alexander Papp,M. Zinda,Craig Marshall +17 more
TL;DR: In combination with gemcitabine, RP-6306 demonstrated tumor regression and superior efficacy compared to single agent treatment of either agent alone in multiple CCNE1 amplified models, including HCC1569 and OVCAR3.
A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma
Isabel Soria-Bretones,Matias Casás-Selves,Elliot Goodfellow,Li Li,Cathy Caron,A. Shiwram,Hyeyeon Kim,Danielle Henry,Nancy Laterreur,Julian Bowlan,Alejandro Álvarez-Quilón,Frédéric Vallée,A. Veloso,Jordan T. F. Young,M. Hyer,S. Morris,C. G. Marshall,Michal Zimmermann +17 more
Abstract B045: Ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in combination with low dose gemcitabine in patients with solid tumors with DNA damage response (DDR) aberrations: Preclinical and Phase 1b results
Ezra Y. Rosen,Timothy A. Yap,Elisa Fontana,Elizabeth K Lee,Devalingam Mahalingam,Martin Højgaard,Niharika B. Mettu,Gregory M. Cote,Ruth Plummer,Ian M. Silverman,J. Schonhoft,Emeline Bacque,Adrian J. Fretland,Gabriela Gomez,Danielle Ulanet,Kezhen Fei,Julia Yang,Maria Koehler,Anne Roulston,Li Li,Michal Zimmermann,Benedito A. Carneiro,Stephanie Lheureux +22 more
TL;DR: Low doses of cam and gem resulted in tumor regression not observed in single agent arms, with good tolerability, in a tumor xenograft model, and myelotoxicity, the most frequent Tx-related toxicity, improved with decreasing gem doses.
Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor.
Frédéric Vallée,Matias Casás-Selves,Monica Bubenik,Martin Duplessis,Boubacar Sow,Catalina Suarez,Bruno Sangiorgi,Li Li,M. Hyer,Robert Papp,Marie-Eve Leclaire,Alexander L. Perryman,Simon Surprenant,Philippe Mochirian,Victor Pau,Z. Maděrová,Pavel Mader,Elliot Goodfellow,Anne Roulston,R. Stocco,Claude Godbout,Prasamit S Baruah,Alexanne Bonneau-Fortin,J. Schonhoft,Parham Nejad,David Norman,V. Truong,Sheldon Crane,Mohamed A Attia,Daniel Mao,Frank Sicheri,C. G. Marshall,Michal Zimmermann,David Bendahan,Michel Gallant,W. C. Black +35 more